Two hundred and ten adult CMV seropositive patients undergoing myeloablative conditioning (MAC) [n ¼ 127] or reduced intensity conditioning (RIC) [n ¼ 83] transplants (HCT) were serially monitored for CMV reactivation and disease, using a qualitative polymerase chain reaction (PCR) followed by quantitation with pp65 antigen or quantitative PCR. CMV reactivation occurred in 53 RIC (63.9%) and 61 MAC (48%; P ¼ 0.03) transplants at a median of 47 days (range: 24-1977). Risk factors identified included acute GVHD (P ¼ 0.001), RIC regimen (P ¼ 0.03), unrelated donor (P ¼ 0.02), use of anti-thymocyte globulin/alemtuzumb (P ¼ 0.02) and use of bone marrow in MAC transplants (P ¼ 0.011). On multivariate analysis, RIC transplants and acute GVHD remained independent predictors. Treatment with antiviral drugs resulted in CMV negativity rates of 86.8% in MAC and 88.6% in RIC transplants. CMV disease occurred in 10.8% of RIC and 4.7% of MAC transplants (P ¼ 0.15). At a median follow-up of 26 months (range: 3-88), 48.1% of RIC and 50.3% of MAC transplants are alive. The higher incidence of CMV reactivation among RIC transplants suggests the need for novel prophylactic or pre-emptive strategies in this high-risk group of patients.
Introduction
The increasing use of reduced intensity conditioning (RIC) transplants has greatly expanded the indications for allogeneic transplants to older patients and a larger number of hematological disorders. 1 The use of intense immunosuppressive regimens in RIC transplants has raised concerns about whether the incidence of infection particularly with CMV would be higher in these transplants but existing data are contradictory. Initial studies suggested that there was no difference in the incidence of CMV reactivation among patients undergoing a nonmyeloablative transplant compared with a conventional myeloablative conditioning (MAC) transplant but more recent studies provide evidence to the contrary. [2] [3] [4] [5] [6] These differences, in part, may be related to the type of patients chosen in the analysis (high-risk sero-positive recipients alone versus all recipients) and also to the differences in the type of conditioning regimen used in these transplants. T-cell depleting agents including alemtuzumab and antithymocyte globulin (ATG) are often included in RIC conditioning regimens and seem to be a major determinant of the risk of CMV. [7] [8] [9] [10] At our institution, we have used a pre-emptive strategy based on of serial monitoring of peripheral blood for CMV viremia with institution of antiviral therapy (ganciclovir or foscarnet) for CMV reactivation. We report a comparison of CMV reactivation rates between RIC and MAC transplants in patients considered high risk for CMV reactivation (that is, seropositive recipients with either seropositive or seronegative donor).
Patients and methods

Patients
This is a retrospective analysis of consecutive adult patients who underwent allogeneic HCT at our center using either a fludarabine-based RIC or a MAC between January 2001 and June 2008. The data were collected from the transplant database and individual medical records. This study was approved by the Sydney West Human Research Ethics Committee.
A total of 315 adult patients underwent allogeneic transplant at our center during the study period. Of these, 210 patients, having either RIC or a MAC transplant, were considered high risk based on pre-transplant CMV serostatus (recipient seropositive with donor either negative or positive) and thus were considered for analysis. Patients undergoing cord blood transplant or haploidentical transplants were excluded from this analysis. Patient details are given in Table 1 . One hundred and twenty-seven patients (63.1%) underwent a conventional MAC transplant whereas 83 (36.9%) underwent an RIC transplant. Conditioning regimens used for myeloablative transplants included cyclophosphamide (120 mg/kg) in combination with either fractionated total body irradiation (2 Gy BD Â 3 days) (54.4%) or oral busulfan (16 mg/kg over 4 days) (40.9%). Six patients who received cyclophosphamide (200 mg/kg) in combination with ATG (ATGAM 40 mg/ kg Â 4 days) (4.7%) for aplastic anemia were also included in this group for analysis. RIC regimens were fludarabine non-total body irradiation based and included fludarabine (25 mg/m 2 Â 5) in combination with either cyclophosphamide (120 mg/kg) (57.8%), melphalan (140 mg/m 2 ) (34.9%) or oral busulfan (1 mg/kg Â 10 doses) (7.3%). ATG or alemtuzumab was added to both RIC and MAC regimens for unrelated donor transplants and for a minority of sibling RIC transplants. The median age of RIC transplants (49 years) was significantly higher compared with MAC (39 years; P ¼ 0.005) and a higher number in the RIC arm were transplanted for indications such as lymphoproliferative disorders, multiple myeloma and myelofibrosis. Matched unrelated donors comprised 37.8% of MAC and 25.4 % of RIC transplants (P ¼ 0.08). In RIC transplants, there was a higher use of peripheral blood stem cells as the graft source, as opposed to bone marrow (97.5% versus 77.9%; P ¼ 0.001). The percentage of CMV seronegative donors was similar in both groups (37.8% with MAC, 39.8% with RIC; P ¼ 0.774) ( Table 1) .
Diagnosis and treatment of GVHD Intravenous cyclosporin either alone or in combination with methotrexate or mycophenolate mofetil (MMF) was Table 1 Baseline characteristics of CMV seropositive recipients undergoing HCT 
Supportive care
Intravenous immunoglobulin (Gammagard SD, Baxter, Heidelberg, Germany) was given to all patients weekly till day 100 based on serum IgG levels targeting to maintain normal levels (IgG 46 g/l) during the first 100 days of transplant. All blood products were leukocyte depleted by cell separation or filters.
CMV monitoring and treatment
All CMV seropositive recipients received pre-transplant ganciclovir (5 mg/kg intravenous BD) for 8 days until Day 2. Valaciclovir (500 mg daily) was started on the day of transplant as herpes virus prophylaxis. Serial weekly monitoring for CMV viremia was performed using an inhouse qualitative polymerase chain reaction (PCR) during the entire period of the study. CMV reactivation was defined as the need for institution of antiviral therapy with either ganciclovir or foscarnet. Antiviral therapy was started if CMV quantitation by pp65 antigen was X5 cells/ 200 000 or if the PCR detected 4600 copies/ml. Induction therapy was given for 2 weeks provided patients achieved two negative QT-PCR assay done 3 days apart. CMV disease was diagnosed on demonstration of tissue invasion on biopsy specimens or demonstration of a positive CMV early antigen on bronchoalveolar lavage along with clinical and radiological features consistent with CMV infection. Fourteen patients received CMV-specific cytotoxic T lymphocytes as a part of an ongoing trial in our institution (seven in each arm).
11,12
Statistics Statistical calculations were done with the Statistical Program for Social Science (SPSS, version 10.0). Differences between groups were assessed with Fisher's exact test. Multivariate analysis was calculated by logistic regression analysis. A P-value o0.05 was considered statistically significant.
Results
Incidence of CMV reactivation CMV reactivation was seen in 53 RIC transplants (63.8%) at a median of 47 days post transplant (range: (Table 3) .
Treatment of CMV reactivation and CMV disease
All 114 patients with CMV reactivation received antiviral therapy with either ganciclovir or foscarnet. Resolution of CMV viremia occurred in 100 patients (87.7%) after a median of 21 days (range: 7-64). Resolution was similar among RIC (88.6%) and MAC transplants (86.8%; P ¼ 1.000). Of the 14 patients who did not have resolution of viremia, 8 died of CMV disease whereas 5 died of acute GVHD and 1 expired because of late veno-occlusive disease of the liver. Recurrent CMV reactivation (new episode after resolution of initial episode with antiviral therapy) was seen in 16 patients (7 with MAC and 9 with RIC) and predominantly in those patients with chronic GVHD. CMV disease was diagnosed in six MAC (4.7%) and nine RIC transplants (10.8%; P ¼ 0.153) and occurred at a median of 62 days post HCT for MAC transplants (range: 45 days-46 months) and 49 days for RIC (range: 27-16 months). Two patients each in the RIC and the MAC arms had CMV disease beyond Day 100. The sites of CMV disease were mainly the gastro-intestinal tract (total 10; RIC 6 and MAC 4), lungs (total 4: MAC 1 and RIC 3) and disseminated in 1 (MAC). All patients with pulmonary or disseminated CMV disease expired despite therapy whereas four (40%) patients with GI involvement expired with CMV disease because of GVHD and multiorgan failure (Table 4) .
Overall survival
At a median follow-up of 26 months (range: 3-88), 104 patients (49.5%) are alive. The median follow-up of survivors is 22 months (range: 3-88) for MAC and 29 months (range: 3-87) for RIC transplants. The OS among RIC transplants (48.1%) was similar to MAC transplants (50.3%; P ¼ 0.779) (Figure 1) . The OS among patients who had CMV reactivation (44.7%) was not significantly different from patients without reactivation (55.2%; P ¼ 0.165) (Figure 2 ). Among RIC transplants, patients with CMV reactivation had a similar outcome (OS: 41.5% with reactivation; 60% without reactivation; P ¼ 0.115) as did MAC transplants (OS: 47.5% with reactivation; 53% without reactivation; P ¼ 0.595). 
Discussion
CMV infection remains a major problem after allogeneic HCT especially among seropositive patients at a high risk of CMV reactivation. This retrospective analysis indicates that these patients have a significantly higher incidence of CMV reactivation after an RIC transplant than an MAC transplant. There are conflicting data on the incidence of CMV reactivation in RIC transplants. Junghanss et al. 2 in their study of 56 (CMV high risk n ¼ 34) non-myeloablative transplants showed no difference in the rates of CMV reactivation compared with matched controls who had a conventional transplant but showed a later onset of CMV disease among non-myeloablative transplants. Schetelig et al. 3 and Hill et al. 4 in their studies of 21 and 17 RIC transplants, respectively, showed a higher incidence of CMV reactivation with RIC transplants but could not show a statistically significant difference compared with MAC transplants. The major studies comparing CMV reactivation rates among RIC and MAC transplants are compiled in Table 5 and it is clear from the data that, except for the two studies by Meijer et al. 13, 14 and Junghass et al.
2 five studies show a higher incidence of CMV reactivation with RIC transplants although the differences do not reach statistical significance probably because of the small number of patients studied. Nakamura et al. 15 in their large study of 176 patients showed a significantly higher incidence of CMV reactivation with MAC (83%) compared with RIC transplants but all the MAC transplants had T-cell-depleted grafts that could partly explain the high incidence. Our study, with all the inherent limitations of a retrospective analysis, is the largest to date (210 high-risk patients) comparing CMV reactivation between RIC and MAC transplants. Given the conflicting data present in literature, prospective studies involving a larger number of patients would be necessary to better understand the mechanisms and risk factors of CMV reactivation post HCT. T-cell depletion of the graft and the addition of T-cell depleting agents reduce the risk of acute GVHD but also impair immune reconstitution and have been shown to be associated with a higher incidence of CMV reactivation especially among RIC transplants. [16] [17] [18] Although in general, the onset of CMV reactivation was not delayed among RIC transplants compared with MAC transplants, the addition of the T-cell depleting agents, alemtuzumab or ATG to the RIC protocol led to an earlier onset of CMV infection than with a standard RIC regimen. Interestingly, the use of ATG was not associated with an earlier onset of CMV reactivation in MAC transplants.
As expected, in both RIC and MAC groups, grades II-IV acute GVHD was associated with a higher incidence of CMV reactivation, consistent with previously published data. It is well accepted that grades II-IV acute GVHD is not only associated with a higher incidence of CMV reactivation but also with a higher incidence of CMV disease. 19, 20 However, among patients who did not develop GVHD (n ¼ 84), the incidence of CMV reactivation was significantly increased in those who underwent RIC transplant compared with MAC (53.6% versus 20.9%; P ¼ 0.003). Interestingly, among patients where T-cell depleting agents (ATG or alemtuzumab) were not used (n ¼ 136), the incidence of CMV reactivation remained high among RIC transplants (59.2% versus 41.4%; P ¼ 0.05) compared with MAC.
In our study, there was no significant difference in the rates of CMV reactivation between the different RIC regimens (Flu/Mel versus Flu/Bu versus Flu/Cy) although the number of cases in each subgroup was small. The mechanism by which a RIC regimen is associated with an increased risk of CMV reactivation is unclear. Almost all RIC regimens now incorporate fludarabine, a potent T-cell immunosuppressant. However, the pharmacokinetics of fludarabine indicates that this drug is unlikely to affect donor T cells infused with the stem cell graft and thus alter the reconstitution of specific cellular immunity to CMV. CD8 þ T lymphocytes and natural killer cells have an important function in maintaining cell-mediated immunity against CMV and suppressing viral replication, 21, 22 and inadequate or defective recovery of CD8 þ T cells after transplant has been shown to contribute to a higher incidence of CMV reactivation and disease in transplant recipients. [23] [24] [25] [26] [27] Though previous studies have showed similar patterns of immune reconstitution after non-myeloablative transplantation compared with myeloablative transplants, 28 the use of ATG or alemtuzumab has been shown to delay CMV-specific immune reconstitution. 8, 9, 10, 17 In this study, the OS among patients with CMV reactivation was not significantly lower than patients without CMV reactivation. Previous published data have suggested that recipient CMV seropositivity itself was associated with higher mortality rates. 29, 30 Among RIC transplants, there was a trend toward a better OS in patients without CMV reactivation (OS 60%) compared with patients with CMV reactivation (OS 41.5%; P ¼ 0.115). Previous studies on CMV reactivation in patients undergoing an RIC transplant, however, have not suggested an adverse effect of reactivation on OS. 8 The higher incidence of CMV reactivation among RIC transplants and its possible impact on OS suggests that novel strategies are required in CMV seropositive patients receiving RIC transplants. These include consistent use of existing antiviral prophylaxis, enhanced surveillance, use of newer agents such as maribavir and the use of adoptive immunotherapy. 31, 32 In conclusion, among CMV seropositive recipients, the use of a fludarabine-based RIC regimen is associated with a significantly higher incidence of CMV reactivation compared with myeloablative transplants. This difference is independent of the presence of acute GVHD and the additional use of T-cell depleting agents such as alemtuzumab and ATG in the conditioning regimen. A larger number of high-risk patients undergoing RIC transplant needs to be studied to understand the full impact of CMV reactivation. Better prophylactic strategies are required to reduce rates of CMV reactivation and disease and improve survival among patients undergoing RIC transplants. 
